Gallo Juan E, Ochoa Juan E, Warren Helen R, Misas Elizabeth, Correa Monica M, Gallo-Villegas Jaime A, Bedoya Gabriel, Aristizábal Dagnóvar, McEwen Juan G, Caulfield Mark J, Parati Gianfranco, Clay Oliver K
Cellular & Molecular Biology Unit, Corporación para Investigaciones Biológicas, Medellín, Colombia.
Doctoral Program in Biomedical Sciences, Universidad del Rosario, Bogotá, Colombia.
Int J Cardiol Hypertens. 2020 Dec;7:100050. doi: 10.1016/j.ijchy.2020.100050. Epub 2020 Sep 15.
The band 9p21.3 contains an established genomic risk zone for cardiovascular disease (CVD). Since the initial 2007 Wellcome Trust Case Control Consortium study (WTCCC), the increased CVD risk associated with 9p21.3 has been confirmed by multiple studies in different continents. However, many years later there was still no confirmed report of a corresponding association of 9p21.3 with hypertension, a major CV risk factor, nor with blood pressure (BP).
In this contribution, we review the bipartite haplotype structure of the 9p21.3 risk locus: one block is devoid of protein-coding genes but contains the lead CVD risk SNPs, while the other block contains the first exon and regulatory DNA of the gene for the cell cycle inhibitor p15. We consider how findings from molecular biology offer possibilities of an involvement of p15 in hypertension etiology, with expression of the p15 gene modulated by genetic variation from within the 9p21.3 risk locus.
We present original results from a Colombian study revealing moderate but persistent association signals for BP and hypertension within the classic 9p21.3 CVD risk locus. These SNPs are mostly confined to a 'hypertension island' that spans less than 60 kb and coincides with the p15 haplotype block. We find confirmation in data originating from much larger, recent European BP studies, albeit with opposite effect directions.
Although more work will be needed to elucidate possible mechanisms, previous findings and new data prompt reconsidering the question of how variation in 9p21.3 might influence hypertension components of cardiovascular risk.
9号染色体短臂21.3区是一个已确定的心血管疾病(CVD)基因组风险区域。自2007年威康信托病例对照研究联盟(WTCCC)的首次研究以来,9p21.3与心血管疾病风险增加之间的关联已在不同大陆的多项研究中得到证实。然而,多年后仍没有关于9p21.3与主要心血管危险因素高血压以及血压(BP)之间相应关联的确切报道。
在本论文中,我们回顾了9p21.3风险位点的二分单倍型结构:一个区域没有蛋白质编码基因,但包含主要的心血管疾病风险单核苷酸多态性(SNP),而另一个区域包含细胞周期抑制剂p15基因的第一个外显子和调控DNA。我们考虑分子生物学的研究结果如何提示p15参与高血压病因的可能性,p15基因的表达受9p21.3风险位点内遗传变异的调控。
我们展示了一项哥伦比亚研究的原始结果,该结果揭示了经典的9p21.3心血管疾病风险位点内血压和高血压存在中度但持续的关联信号。这些SNP大多局限于一个跨度小于60 kb的“高血压岛”,该区域与p15单倍型区域重合。我们在来自近期更大规模欧洲血压研究的数据中得到了证实,尽管效应方向相反。
尽管需要更多工作来阐明可能的机制,但先前的研究结果和新数据促使我们重新思考9p21.3的变异如何影响心血管风险中的高血压成分这一问题。